# Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

> **NCT04480138** · PHASE2 · TERMINATED · sponsor: **Zydus Lifesciences Limited** · enrollment: 7 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Pegylated Interferon-α2b
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04480138
- **Lead sponsor:** Zydus Lifesciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-11
- **Primary completion:** 2021-06-21
- **Final completion:** 2021-06-21
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Due to non availability of eligible subjects and slow recruitment
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480138, "Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04480138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*